Anti-gliadin Antibodies and Gluten Neuropathies: A Borderline Link

The aim of this research was to estimate the prevalence of gluten sensitivity in neurologic diseases of unknown etiology and to determine their clinical and biological characteristics in a Moroccan population.

Patients and Methods: A prospective case-control study was performed on 60 patients and 57 controls. Patients and controls underwent a screening for IgG and IgA anti-gliadin antibodies (ELISA anti-Gliadin, Orgentec, threshold: 12 IU/ml), and IgA anti-tissue transglutaminase antibodies (ELISA IgA-tGTA, DRG, threshold: 10 IU/m).

Results: The median age of patients was 43±13.91 years (ranges: 13-67), versus 39.4±9.12 (ranges: 19-58) for controls. Male to female sexe-ratio was 0.7 for patients vs 2.1 for controls. IgG and/or IgA anti-gliadin antibodies (AGA) were positive in 26.7% of cases (n=16) vs 15.8% (n=9) in controls (p=0.15), while IgA-tTGA was negative in all patients, but positive in 1 control. Positive AGA cases corresponded to peripheral neuropathy (n=4), ataxia (n=3), ischemic stroke (n=3), myopathy (n=2), and 1 case for each of the following conditions: multiple sclerosis, epilepsy, cerebral thrombophlebitis and myelopathy. Among the positive AGA cases, IgA isotype was more prevalent, but IgG AGA titers were higher and clinically more relevant.

Conclusion: Gluten Sensitivity is a potential cause of unknown etiological neurologic diseases in young adults, particularly peripheral neuropathy, ataxia and ischemic stroke. AGA testing especially IgG isotype might be a suitable marker to screen for gluten neuropathies.